XAV-19

DRUG2 trials

Sponsors

Nantes University Hospital, Xenothera SAS

Conditions

COVID-19SARS Virus

Phase 2

Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia

CompletedNCT04453384

Nantes University HospitalSARS Virus

Start: 2020-09-01End: 2021-08-19Updated: 2022-03-25

Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

TerminatedNCT04928430

Xenothera SASCOVID-19

Start: 2021-04-28End: 2022-11-28Updated: 2023-01-23

Related Papers

Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19

Frontiers in Immunology2024-04-173 citations

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

Frontiers in Immunology2021-11-1512 citations

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study.

2021-08-1717 citations

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.

2021-03-0915 citations